TLPH
TalpheraยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
TLPH Profile
Talphera, Inc.
A specialty pharmaceutical company that develops therapies for acute post-operative pain and cancer breakthrough pain
1850 Gateway Drive, Suite 175, San Mateo, CA 94404
--
Talphera, Inc., was originally registered in Delaware as SuRX, Inc., on July 13, 2005. The company subsequently changed its name to AcelRx Pharmaceuticals, and the company changed its name from "AcelRx Pharmaceuticals, Inc." to "Talphera, Inc." on January 10, 2024. The Company is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for medical regulatory settings. Talphera's lead product candidate, Niyad, a lyophilized formulation of nafamostat, is currently being studied under the Research Device Exemption (IDE) as an anticoagulant for the in vitro circuit and has received Breakthrough Device Designation status from the FDA. Talphera is also developing two pre-filled syringes licensed from partner Aguettant: Fedsyra, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
